#United States #Anixa Biosciences #San Jose #CAR-T therapy #Ovarian Cancer

Anixa Biosciences Advances Ovarian Cancer Treatment

Anixa Biosciences, Inc., a leading biotechnology firm publicly traded on NASDAQ under the ticker ANIX, has made significant strides in its clinical trial for a novel CAR-T therapy aimed at treating recurrent ovarian cancer. On October 1, 2026, Anixa announced that the second patient in the fifth cohort of its Phase 1 clinical trial has been treated. This remarkable milestone is part of a dose-escalating study assessing the safety and preliminary efficacy of a specialized CAR-T strategy that targets the follicle-stimulating hormone receptor (FSHR), a crucial marker expressed predominantly on ovarian cancer cells.

The trial is being conducted at the renowned Moffitt Cancer Center, which is known for its cutting-edge work in cancer treatment and research. The current cohort participants receive 1×10⁷ CAR-positive cells per kilogram of their body weight, following a process known as lymphodepletion. This represents the highest dose used to date in the study, and notably, there have been no observed dose-limiting toxicities in patients treated, including the first patient from this cohort.

Encouraging Patient Outcomes

Dr. Amit Kumar, the Chairman and CEO of Anixa Biosciences, expressed optimism about the trial results so far. He emphasized that ovarian cancer is particularly deadly, especially for those facing recurring symptoms who have had few effective treatment options. Encouragingly, several patients in previous cohorts have achieved over a year of survival following treatment. Remarkably, one patient has even surpassed two years. In stark contrast, patients with similar profiles typically survive just a matter of weeks.

To date, the first four patients who have completed treatment under this trial have reported survival times of approximately 28 months, 19 months, 17 months, and 17 months, respectively. Such outcomes are notable, particularly given the advanced level of treatment these patients had previously undergone. The potential for this CAR-T therapy to provide prolonged survival in a cohort that has historically struggled for effective solutions is a reason for celebration within the medical community.

The Technology Behind the Therapy

Anixa’s CAR-T technology has its roots in pioneering work by Dr. Jose R. Conejo-Garcia of Duke University, known for his expertise in immunology. At Anixa, this technology has evolved into an innovative approach through a type called chimeric endocrine receptor-T cell (CER-T) therapy. This model distinguishes itself from traditional CAR-T therapies, as it utilizes the natural ligand of the FSHR receptor instead of the more common antibody fragments. This mechanism holds immense promise for reducing side effects while enhancing the treatment efficacy.

The clinical trial is overseen by Dr. Robert Wenham, the Chair of the Gynecologic Oncology Program at Moffitt. Under his leadership, the team is cautiously optimistic about the outcomes that could redefine treatment paradigms for ovarian cancer – one of the most challenging cancers to treat effectively.

Future Prospects and Collaborations

Anixa Biosciences maintains a visionary model by partnering with leading research institutions. Besides its CAR-T initiatives, the company is collaborating with the Cleveland Clinic to develop vaccines targeting various cancers, including breast and ovarian cancers. This diversification in research efforts enhances their potential to contribute meaningful innovations to the oncology landscape.

In conclusion, the progress made by Anixa in their CAR-T clinical trial for ovarian cancer is encouraging. The promising outcomes of prolonged survival and negligible side effects position this biotechnology firm as a significant player in the fight against one of the most deadly forms of cancer. As enrollment continues and more data emerges, the medical community watches with hope.